Paul Hastings Advised J.P. Morgan, Leerink Partners in Connection With Lexeo Therapuetics' PIPE
March 12, 2024
March 12, 2024
LOS ANGELES, California, March 12 -- Paul Hastings, a law firm, issued the following news:
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in connection with Lexeo Therapeutics' private placement (PIPE).
The PIPE consists of the sale of 6,278,905 shares of common stock at a price of $15.13 per share. Lexeo Therapeutics (Nasdaq: LXEO) is clinical stage genetic medicine company dedicated to pionee . . .
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in connection with Lexeo Therapeutics' private placement (PIPE).
The PIPE consists of the sale of 6,278,905 shares of common stock at a price of $15.13 per share. Lexeo Therapeutics (Nasdaq: LXEO) is clinical stage genetic medicine company dedicated to pionee . . .